The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 VaccineArticle Published on 2024-01-152024-09-05 Journal: Vaccines [Category] update2024, [키워드] ankylosing spondylitis COVID-19 herpes zoster mRNA vaccine psoriatic arthritis spondyloarthritis [DOI] 10.3390/vaccines12010085 PMC 바로가기 [Article Type] Article
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virusReview Published on 2023-04-012023-05-31 Journal: Expert opinion on pharmacotherapy [Category] 두창, 수두, 홍역, [키워드] bDMARDs cDMARDs herpes zoster HZ jak inhibitors rheumatoid arthritis spondyloarthritis [DOI] 10.1080/14656566.2023.2195050 [Article Type] Review
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studiesArticle Published on 2023-03-012023-06-01 Journal: Rheumatology International [Category] 두창, 수두, 홍역, [키워드] herpes zoster jak inhibitors rheumatoid arthritis spondyloarthritis systematic review ulcerative colitis [DOI] 10.1007/s00296-022-05270-6 PMC 바로가기
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort studyArticle Published on 2022-10-052022-11-15 Journal: BMC Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI analyzed anti-RBD antibodies binding antibody antibody level blood sample bowel collected combination treatment Control controls COVID-19 declined defined disease dose enrolled Factor greater healthy healthy control healthy individuals Humoral immunity identify Immune-mediated inflammatory disease immunosuppressive Immunosuppressive medication Inflammatory bowel disease inhibitor initial interval median Multivariable regression Necrosis participant Patient patients persistence prospective cohort study Protein provided psoriatic arthritis RBD reduction reduction in Rheumatic diseases rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine serologic Serologic response spike spondyloarthritis Support the receptor-binding domain the SARS-CoV-2 Therapies therapy ulcerative colitis vaccination vaccine dose [DOI] 10.1186/s12916-022-02587-8 PMC 바로가기
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugsArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome adverse event antibody concentration axial spondyloarthritis biological disease-modifying drug BNT162b2 BNT162b2 vaccine booster booster doses booster vaccination clinical questionnaire Cohort cohorts comparable coronavirus disease Coronavirus-2 COVID-19 enrolled evaluated Evidence flow cytometric General population healthy control humoral IL-17 immune response Immune-mediated inflammatory disease immunogenicity individuals inhibitor inhibitors intracellular cytokine investigated male no difference outcome Patient patients patients treated peptide-based persistence prospective observational study Responder Safety SARS-CoV-2 Specific spondyloarthritis subgroups T-cell T-cell immune response T-cell Response therapy TNFα treated tumor necrosis factor-alpha vaccination virus-neutralizing antibody were assessed [DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccinationArticle Published on 2022-09-012022-11-15 Journal: RMD Open [Category] SARS, 진단, [키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination [DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기
Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registryArticle Published on 2022-09-012023-08-30 Journal: RMD Open [Category] E형 간염, [키워드] COVID-19 Epidemiology spondyloarthritis [DOI] 10.1136/rmdopen-2022-002447 PMC 바로가기
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort진행중인 미코페놀레이트 치료는 만성 염증성 자가면역 질환 또는 간 이식 수혜자의 영향을 받는 환자에서 항-SARS-CoV-2 백신 반응을 손상시킵니다: RIVALSA 예상 코호트의 결과Observational Study Published on 2022-08-122022-09-11 Journal: Viruses [Category] SARS, 임상, 진단, 치료기술, [키워드] 95% CI administration Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG anti-SARS-CoV-2 vaccination Antibody Response Antibody titers ARMS Arthritis Autoimmune Autoimmune disease Autoimmune diseases Autoimmune hepatitis calcineurin calcineurin inhibitors chronic cohort of patients Complete connective tissue disease Connective tissue diseases detectable develop Diagnosis dose dose reduction Effect effective Eligible patients enrolled evaluate evaluated example first dose healthy subjects hepatology identify IgG immunogenicity immunosuppressive immunosuppressive therapy Immunosuppressive treatment independent predictor independent predictors individual inhibitor liver liver transplant Liver transplantation MMF mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA vaccine mRNA-based Multivariate analysis mycophenolate mycophenolate. neoplasia Novara observational study organ other diseases overlapped Patient patients performed predictor Prevent Prospective prospective observational study receiving recipients rejection required response Result rheumatoid arthritis rheumatological SARS-COV-2 infection selected Seroconversion seroconversion failure spondyloarthritis subgroups of patient suffered Suspension Tertiary therapy transplantation transplants treated Treatment unit Univariate analysis university vaccinated individual vaccination Vaccine vaccine response Vasculitis [DOI] 10.3390/v14081766 PMC 바로가기 [Article Type] Observational Study
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy면역억제 요법을 받는 환자에서 표준 및 3차 접종 SARS-CoV-2 백신 접종의 면역원성과 안전성Observational Study Published on 2022-08-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adult patient adverse event age antibody arbitrary unit characterized combination therapy comparable Control controls defined disease dose evaluate facilitate full-length healthy healthy control healthy controls IgG antibody Immune-mediated inflammatory disease immunogenicity immunosuppressive inhibitor interquartile range jak inhibitors lowest median Necrosis Patient patient group patients performed predictor proportion prospective observational study psoriatic arthritis RBD receiving regimen Responder responders rheumatoid arthritis risk RNA-1273 Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serologic response Spike protein spondyloarthritis Standard Support the receptor-binding domain the SARS-CoV-2 therapy ulcerative colitis vaccination Vaccine vaccine dose vaccine response [DOI] 10.1002/art.42153 PMC 바로가기 [Article Type] Observational Study
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trialResearch article Published on 2022-06-272022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 임상, 치료법, [키워드] 1:1 95% CI administration age Analysis Antibody Response Antibody titre Arthritis assigned atopic dermatitis booster Booster vaccine clinics COVID-19 COVID-19 vaccination COVID-19 vaccination programme COVID-19 vaccine data analyst Dermatology diagnosed domain dose Effect Efficacy evaluated female finding funding geometric geometric mean ratio GMR groups hospital Immune-mediated Immune-mediated inflammatory disease Immune-mediated inflammatory diseases Immunity inflammatory condition inflammatory disease inhibit intention-to-treat population interim analysis Intervention investigators Laboratory low-dose methotrexate mixed-effects model multicentre open label Open-label parallel-group participant Participants Patient platform Primary outcome randomisation randomised Randomly receiving recruited recruitment Registered Research researcher rheumatoid arthritis rheumatology SARS-CoV-2 SARS-COV-2 infection Serious Adverse Events Spike protein spondyloarthritis susceptible systemic lupus erythematosus the SARS-CoV-2 translate Treatment treatment as usual Trial Two-arm vaccination Vaccine vaccine dose Vaccine-induced immunity [DOI] 10.1016/S2213-2600(22)00186-2 [Article Type] Research article